Who are Neuphoria Therapeutics Inc.'s main suppliers?

Neuphoria Therapeutics Inc. (NEUP) key suppliers include: MERCK-SHARP-DOHME-CORP, CARINA-BIOTECH, CMOS, CROS, Ironwood Pharmaceuticals, Inc. and 1 more. View the full supplier network at chainsifter.com/chain/NEUP.

Who are Neuphoria Therapeutics Inc.'s major customers?

Neuphoria Therapeutics Inc. (NEUP) key customers include: CARINA-BIOTECH, Merck & Co., Inc., Merck & Co., Inc., Ironwood Pharmaceuticals, Inc., Ironwood Pharmaceuticals, Inc. and 2 more. View the full customer network at chainsifter.com/chain/NEUP.

What sector is Neuphoria Therapeutics Inc. in?

Neuphoria Therapeutics Inc. (NEUP) operates in the general sector. ChainSifter tracks its verified supply chain relationships including suppliers, customers, and strategic partners.

Neuphoria Therapeutics Inc. Suppliers, Customers & Supply Chain (NEUP)

6Suppliers

7Customers

2Debt Items

20Related Chains

Source-Backed Evidence Depth

Neuphoria Therapeutics Inc. (NEUP) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.

16Total relationships

4Distinct source URLs

10High confidence

0.816Average confidence

2026-10-28Latest database update

ChainSifter does not infer unreported suppliers, customers, ownership, acquisitions, debt exposure, revenue dependency, or future supply-chain events on this public page.

Neuphoria Therapeutics Inc. Suppliers

Ticker	Name	Confidence	Evidence
MERCK-SHARP-DOHME-CORP	MERCK-SHARP-DOHME-CORP	92%	we granted MSD (i) an exclusive (even as to us and our affiliates), worldwide, sublicensable license under certain of our patent rights and know-how to research, develop, make, have made, use, offer …
CARINA-BIOTECH	CARINA-BIOTECH	90%	we granted Carina Biotech an exclusive, worldwide license, with the right to grant sublicenses
CMOS	CMOS	90%	expenses incurred under agreements with third parties, including CROs that conduct research, preclinical activities and clinical trials on our behalf as well as CMOs that manufacture our product cand…
CROS	CROS	90%	expenses incurred under agreements with third parties, including CROs that conduct research, preclinical activities and clinical trials on our behalf as well as CMOs that manufacture our product cand…
IRWD	Ironwood Pharmaceuticals, Inc.	72%	obtain regulatory approvals, manufacture a commercial scale product, or arrange for a third party to do so on our behalf or conduct sales and marketing activities necessary for successful product com…
IRWD	Ironwood Pharmaceuticals, Inc.	72%	Reciprocal relationship from IRWD graph: Reciprocal relationship from NEUP graph: Reciprocal relationship from IRWD graph: Reciprocal relationship from NEUP graph: obtain regulatory approvals, manufa…

Neuphoria Therapeutics Inc. Customers

Ticker	Name	Confidence	Evidence
CARINA-BIOTECH	CARINA-BIOTECH	92%	On October 30, 2024, Carina made a milestone payment to the Company in the gross amount of A$1,000,000 which was recorded as revenue during the nine months ended March 31, 2025.
MRK	Merck & Co., Inc.	85%	the Carina Biotech License, and $67.9 million from Australian research and development credits and government grants and assistance.
MRK	Merck & Co., Inc.	85%	Reciprocal relationship from MRK graph: Reciprocal relationship from NEUP graph: the Carina Biotech License, and $67.9 million from Australian research and development credits and government grants a…
IRWD	Ironwood Pharmaceuticals, Inc.	72%	obtain regulatory approvals, manufacture a commercial scale product, or arrange for a third party to do so on our behalf or conduct sales and marketing activities necessary for successful product com…
IRWD	Ironwood Pharmaceuticals, Inc.	72%	Reciprocal relationship from IRWD graph: Reciprocal relationship from NEUP graph: obtain regulatory approvals, manufacture a commercial scale product, or arrange for a third party to do so on our beh…
ARMISTICE-CAPITAL-MASTER-FUND-LTD	ARMISTICE-CAPITAL-MASTER-FUND-LTD	62%	n the warrant and contingent consideration liabilities, and a $3.1 million year-over-year change in working capital. Investing Activities There were no transactions categorized as investing activitie…
CARINA-BIOTECH-PTY-LTD	CARINA-BIOTECH-PTY-LTD	62%	rmine to continue the clinical trial in BNC 210 for PTSD or potentially divest of this asset. We may never succeed in achieving regulatory approval for any of our product candidates. We may obtain un…

Neuphoria Therapeutics Inc. Debt Obligations

Instrument	Description	Confidence	Evidence
NEUP-DEBT-11227	Warrants outstanding: 409	90%	xbrl warrant detail from xbrl 2025-06-30.
NEUP-DEBT	Debt stack $34,225	90%	Market cache reports total debt of $34,225.

Neuphoria Therapeutics Inc. Acquisitions

No acquisitions on recordNo completed or pending acquisitions found in our database for Neuphoria Therapeutics Inc..

Neuphoria Therapeutics Inc. Ownership

Holder	Name	Confidence	Evidence
NEUP-OWNER-LYNX1-CAPITAL-MANAGEMENT-LP	Lynx1 Capital Management LP	90%	13F overlay lists Lynx1 Capital Management LP as top holder; 19 tracked holders.

Neuphoria Therapeutics Inc. Extended Supply Chain Network

Ticker	Name	Chain Index	Hops
TBPH	Theravance Biopharma, Inc.	100.00	2
MGNX	MacroGenics, Inc.	100.00	2
PSNL	Personalis, Inc.	100.00	2
IBIO	iBio, Inc.	100.00	2
JAGX	Jaguar Health, Inc.	100.00	2
MCUJF	Medicure Inc.	100.00	2
EVAX	Evaxion A/S	100.00	2
ENLV	Enlivex Ltd.	100.00	2
HOWL	Werewolf Therapeutics, Inc.	100.00	2
IBRX	ImmunityBio, Inc.	100.00	2
IMMP	Immutep Limited	100.00	2
DYN	Dyne Therapeutics, Inc.	100.00	2
CTMX	CytomX Therapeutics, Inc.	100.00	2
BNBX	BNB Plus Corp.	100.00	2
SDGR	Schrödinger, Inc.	100.00	2
CPMV	Mosaic ImmunoEngineering, Inc.	100.00	2
BMY	Bristol-Myers Squibb Company	100.00	2
ADAG	Adagene Inc.	100.00	2
EDSA	Edesa Biotech, Inc.	100.00	2
STKH	Steakholder Foods Ltd.	100.00	2

Neuphoria Therapeutics Inc. Supply Chain